US 12,403,153 B2
Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
Guillaume Bermond, Epalinges (CH); Laurent Garçon, Velaux (FR); Matthias Canault, Velaux (FR); and Cecile Cros, Epalinges (CH)
Assigned to Nuvamid SA, Epalinges (CH)
Appl. No. 18/028,080
Filed by Nuvamid SA, Epalinges (CH)
PCT Filed Dec. 17, 2021, PCT No. PCT/EP2021/086437
§ 371(c)(1), (2) Date Mar. 23, 2023,
PCT Pub. No. WO2022/129490, PCT Pub. Date Jun. 23, 2022.
Claims priority of application No. 20215833 (EP), filed on Dec. 18, 2020.
Prior Publication US 2023/0330124 A1, Oct. 19, 2023
Int. Cl. A61K 31/706 (2006.01); A61K 31/198 (2006.01); A61P 7/06 (2006.01)
CPC A61K 31/706 (2013.01) [A61K 31/198 (2013.01); A61P 7/06 (2018.01)] 9 Claims
 
1. A method of treatment of sickle cell disease, the method comprising the administration of a compound selected from the group consisting of compounds of formulas 001, 002, 003, 004, 009, 010, 011, 012, 013, 014, and pharmaceutically acceptable salts, crystals, and solvates thereof:

OG Complex Work Unit Chemistry